Suzhou Bioreinno Biotechnology Ltd. Co. has identified antibody-drug conjugates comprising antibodies covalently linked to a cytotoxic drug through a linker. They are reported to be useful for diagnosis and treatment of cancer.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has disclosed crystalline forms of phosphodiesterase PDE4B2 inhibitors. They are reported to be useful for the treatment of chronic obstructive pulmonary disease, interstitial lung diseases and asthma.
Shandong Xiansheng Maidejin Biological Pharmaceutical Co. Ltd. has prepared and tested cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer.
Jiangsu Chia Tai Qingjiang Pharmaceutical Co. Ltd. has synthesized peptide epoxyketone compounds acting as proteasome inhibitors. They are reported to be useful for the treatment of systemic lupus erythematosus, ulcerative colitis and rheumatoid arthritis.
Asieris Pharmaceuticals Co. Ltd. has patented new prodrugs of fibroblast growth factor receptor 3 (FGFR3) inhibitors potentially useful for the treatment of cancer.
A University of Texas System patent describes new YAP1 degradation inducing proteolysis targeting chimeras (PROTACs) designed for use in the treatment of cancer.
Boomray Co. Ltd. has prepared and tested new peptide-drug conjugates comprising a radionuclide-labeled probe linked to a fibroblast activation protein α (FAP)-targeting peptide. They are reported to be useful for the diagnosis and treatment of cancer, inflammation, atherosclerosis, fibrosis and scars.
Gasherbrum Bio Inc. has discovered new glucagon-like peptide 1 receptor (GLP-1R) agonists. They are reported to be useful for the treatment of type 2 diabetes, dyslipidemia, hyperglycemia, hypertension, obesity and more.
RSS